I agree that this site is using cookies. You can find further informations here.
X
ROUSSELOT, N
255  results:
Search for persons X
?
1

Discontinuing statins or not in the elderly? Study protocol..:

Bonnet, Fabrice ; Benard, Antoine ; POULIZAC, P...
info:eu-repo/semantics/altIdentifier/doi/10.1186/s13063-020-04259-5.  , 2020
Link: https://hal.archives-ouv..
 
?
2

Impact of Secured Prescription Implementation for Zolpidem ..:

ROUSSELOT, N ; PARIENTE, Antoine ; MANSIAUX, Yohann.
1544-1709.  , 2020
Link: https://oskar-bordeaux.f..
 
?
3

Discontinuing statins or not in the elderly? Study protocol..:

BONNET, Fabrice ; BENARD, Antoine ; POULIZAC, P...
1745-6215.  , 2020
Link: https://oskar-bordeaux.f..
 
?
4

Information during the "Levothyrox (R) crisis" in France in..:

TAINTURIER, J ; ROUSSELOT, N ; JOSEPH, Jean-Philippe
0998-3953.  , 2020
Link: https://oskar-bordeaux.f..
 
?
5

Development and pilot testing of a tool to assess evidence-..:

ROUSSELOT, N ; TOMBREY, T ; ZONGO, Drissa...
1472-6920 (Electronic) 1472-6920 (Linking).  , 2018
Link: https://oskar-bordeaux.f..
 
?
6

Erratum to "Periostin as a circulating marker for breast ca..:

Contié, S. ; Voorzanger-Rousselot, N. ; Litvin, J...
Bone.  48 (2011)  3 - p. 672 , 2011
Link: https://doi.org/10.1016/..
 
?
7

A combination of multiple serum markers as new tool for the..:

Brinskelle-Schmal, N. ; Voorzanger-Rousselot, N. ; Chassaing, E...
Bone.  47 (2010)  - p. S228-S229 , 2010
Link: https://doi.org/10.1016/..
 
?
8

Multimarker approach for linking bone disorders and cardiov..:

Brinskelle-Schmal, N. ; Hawa, G. ; Voorzanger-Rousselot, N...
Bone.  44 (2009)  - p. S278 , 2009
Link: https://doi.org/10.1016/..
 
?
9

Development of a new ELISA for serum periostin: Growth-rela..:

Contié, S. ; Voorzanger-Rousselot, N. ; Litvin, J....
Bone.  44 (2009)  - p. S270 , 2009
Link: https://doi.org/10.1016/..
 
?
10

93 SERUM DICKKOPF-1 (DKK-1) LEVELS ARE INCREASED IN PATIENT..:

Charni-Ben Tabassi, N. ; Voorzanger-Rousselot, N. ; Juillet, F....
Osteoarthritis and Cartilage.  16 (2008)  - p. S54 , 2008
Link: https://doi.org/10.1016/..
 
?
11

Biochemical markers in oncology. Part I: Molecular basis. P..:

Voorzanger-Rousselot, N. ; Garnero, P.
Cancer Treatment Reviews.  33 (2007)  3 - p. 230-283 , 2007
Link: https://doi.org/10.1016/..
 
?
12

Inactivation of wild-type p53 by a dominant negative mutant..:

Galmarini, C M ; Falette, N ; Tabone, E...
British Journal of Cancer.  85 (2001)  6 - p. 902-908 , 2001
Link: https://doi.org/10.1054/..
 
?
13

P707: DOSE MODIFICATION DYNAMICS OF PONATINIB IN PATIENTS W..:

Apperley, J. ; Kantarjian, H. ; Deininger, M....
HemaSphere.  6 (2022)  - p. 602-603 , 2022
Link: https://doi.org/10.1097/..
 
?
14

Engelures associées à la COVID-19 : comparaison avec le lup..:

Battesti, G. ; El-Khalifa, J. ; Mekki, N....
Annales de Dermatologie et de Vénéréologie.  147 (2020)  12 - p. A193 , 2020
Link: https://doi.org/10.1016/..
 
?
15

PROGNOSTIC VALUE OF INFLAMMATION-BASED ROUTINE BIOMARKERS I..:

Oubaya, N. ; Soubeyran, P. ; Reinald, N....
Journal of Geriatric Oncology.  10 (2019)  6 - p. S9 , 2019
Link: https://doi.org/10.1016/..
 
1-15